

#146

COMPLETE

Collector: Web Link 1 (Web Link)
Started: Saturday, September 20, 2025 7:28:33 PM
Last Modified: Saturday, September 20, 2025 7:33:49 PM
Time Spent: 00:05:16
IP Address: 99.251.201.214

Page 2: Part 1

Q1

Title of activity

New Horizons to Airway Disease Management: Bridging Science and Clinical Practice

Q2

Date of activity

Oct 16, 2025

Q3

Speaker

What is your role in the CPD activity? (Select all that apply)

Q4

Combination - Community and Academic

What's your practice type?

Q5

Please indicate:

I DO NOT have a relationship with a for-profit and/or a not-for-profit organization to disclose. (Skip questions 5 to 9)

Q6

Respondent skipped this question

Any direct financial payments including receipt of honoraria

Q7

Membership on advisory boards or speakers' bureaus

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

Speakers' bureau and/or advisory boards: ALK, AstraZeneca, Bausch Health, Biocryst, CSL Behring, GSK, Novartis, Sanofi, Takeda.

Description of relationship(s)

Speaking or consulting

Q8

Funded grants or clinical trials

Respondent skipped this question

Q9

Patents on a drug, product or device

Respondent skipped this question

Q10

All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity

Respondent skipped this question

Page 3: Part 2: To be completed by presenters only

Q11

I intend to use trade names during my presentation. Note: Only generic names should be used whenever possible. If trade names are used, they should be accompanied by the generic name.

No

Q12

I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication). Note: You must declare all off-label use to the audience during your presentation.

No

Q13

If you answered "Yes" to the previous question, are the medications recommended manufactured by companies you have received funding from?

Respondent skipped this question

Q14

Yes

I acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.

Page 4: Part 3 (Anonymous & Optional): Equity, Diversity and Inclusion (EDI)

Q15

Yes

I confirm that I've completed the EDI Survey linked above

Page 5: PART 4: Acknowledgement and signature (for all)

Q16

First Name:

Harold

Q17

Last Name:

KIM

Q18

He/Him

Gender Pronouns - How would you like us to address you?

Q19

I confirm that the above information is accurate and complete.

Please review and check the items below.
